Syntekabio announced its participation at the BIO International Convention 2024, where the company will highlight its innovative AI-driven drug discovery technologies. The convention will be held June 3-6, 2024, at the San Diego Convention Center, San Diego, CA. At the convention, Syntekabio will showcase DeepMatcherTM, its versatile, disease-agnostic platform that generates small molecule hits, leads, and drug candidates against multiple targets.

Additionally, the company will highlight its in-silico biologics platforms, Neo-ARSTM and Ab-ARSTM, which enable personalized or universal neoantigen cancer vaccine and novel antibody drug prediction, respectively. These cutting-edge solutions address complex challenges in drug discovery, equipping researchers with powerful tools to develop novel and effective therapeutics.